Reboxetine (CHEM002148)
| Record Information | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Version | 1.0 | ||||||||
| Creation Date | 2009-07-21 20:26:21 UTC | ||||||||
| Update Date | 2026-05-14 16:24:50 UTC | ||||||||
| Accession Number | CHEM002148 | ||||||||
| Identification | |||||||||
| Common Name | Reboxetine | ||||||||
| Class | Small Molecule | ||||||||
| Description | Reboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD. Its mesylate (i.e. methanesulfonate) salt is sold under tradenames including Edronax, Norebox, Prolift, Solvex, Davedax or Vestra. Reboxetine has two chiral centers, but it only exists as two enantiomers, (R,R)-(-)- and (S,S)-(+)-reboxetine. | ||||||||
| Contaminant Sources |
| ||||||||
| Contaminant Type |
| ||||||||
| Chemical Structure |  | ||||||||
| Synonyms | Not Available | ||||||||
| Chemical Formula | C19H23NO3 | ||||||||
| Average Molecular Mass | 313.391 g/mol | ||||||||
| Monoisotopic Mass | 313.168 g/mol | ||||||||
| CAS Registry Number | 98769-81-4 | ||||||||
| IUPAC Name | (2R)-2-[(R)-(2-ethoxyphenoxy)(phenyl)methyl]morpholine | ||||||||
| Traditional Name | Not Available | ||||||||
| SMILES | [H][C@](OC1=CC=CC=C1OCC)(C1=CC=CC=C1)[C@]1([H])CNCCO1 | ||||||||
| InChI Identifier | InChI=1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3/t18-,19-/m0/s1 | ||||||||
| InChI Key | InChIKey=CBQGYUDMJHNJBX-OALUTQOASA-N | ||||||||
| Chemical Taxonomy | |||||||||
| Classification | Not classified | ||||||||
| Biological Properties | |||||||||
| Status | Detected and Not Quantified | ||||||||
| Origin | Exogenous | ||||||||
| Cellular Locations |
| ||||||||
| Biofluid Locations | Not Available | ||||||||
| Tissue Locations | Not Available | ||||||||
| Pathways | Not Available | ||||||||
| Applications | Not Available | ||||||||
| Biological Roles | Not Available | ||||||||
| Chemical Roles | Not Available | ||||||||
| Physical Properties | |||||||||
| State | Solid | ||||||||
| Appearance | White powder. | ||||||||
| Experimental Properties |
| ||||||||
| Predicted Properties | Not Available | ||||||||
| Spectra | |||||||||
| Spectra |
| ||||||||
| Toxicity Profile | |||||||||
| Route of Exposure | Reboxetine is rapidly and extensively absorbed following oral administration. | ||||||||
| Mechanism of Toxicity | Reboxetine is a selective inhibitor of noradrenaline reuptake. It inhibits noradrenaline reuptake in vitro to a similar extent to the tricyclic antidepressant desmethylimipramine. Reboxetine does not affect dopamine or serotonin reuptake and it has low in vivo and in vitro affinity for adrenergic, cholinergic, histaminergic, dopaminergic and serotonergic receptors. | ||||||||
| Metabolism | Reboxetine is metabolized by dealkylation, hydroxylation and oxidation followed by glucuronide or sulphate conjugation. It is metabolized by the cytochrome P450 CYP isoenzyme 3A4. Half Life: 12.5 hours | ||||||||
| Toxicity Values | Not Available | ||||||||
| Lethal Dose | Not Available | ||||||||
| Carcinogenicity (IARC Classification) | No indication of carcinogenicity to humans (not listed by IARC). | ||||||||
| Uses/Sources | For the treatment of clinical depression. | ||||||||
| Minimum Risk Level | Not Available | ||||||||
| Health Effects | Not Available | ||||||||
| Symptoms | Reports of seizures (rare) have been reported | ||||||||
| Treatment | Not Available | ||||||||
| Concentrations | |||||||||
| Not Available | |||||||||
| External Links | |||||||||
| Identifiers | Not Available | ||||||||
| References | |||||||||
| Synthesis Reference | Not Available | ||||||||
| MSDS | Not Available | ||||||||
| General References | Not Available | ||||||||
